EU Backs Local Ready-to-Use Therapeutic Food Production

The European Union launched a vital partnership with Nigeria to finance the domestic manufacture of Ready-to-Use Therapeutic Food. This collaborative initiative aims to end the country’s costly reliance on imported nutritional treatments for severe acute malnutrition. Massimo De Luca, the Head of Cooperation for the EU Delegation to Nigeria, announced the intervention at a specialized industrial summit in Abuja. The programme shifts the strategy from foreign aid dependency toward building sustainable internal manufacturing capacity. Localising this production line will insulate vulnerable communities from international supply shocks and fluctuating freight costs.

The funding model relies heavily on co-financing mechanisms that bring together international donors, state governments, and private manufacturing partners. To kickstart the domestic supply chain, the European Union is deploying capital to upgrade processing facilities so they meet strict global food safety standards. Local factories must secure World Health Organisation certification before they can supply regional humanitarian distribution networks. This technical assistance helps domestic agro-processors bridge the quality gap that previously disqualified them from major international procurement contracts.

Nigeria currently faces a severe malnutrition crisis, particularly across its northern regions, where conflict and climate pressures disrupt agricultural output. Importing therapeutic foods from overseas factories remains a prohibitively slow and expensive way to address a rolling public health emergency. The new domestic production model relies on locally sourced agricultural inputs, primarily groundnuts, soybeans, and essential grains. By linking manufacturing directly to Nigerian farms, the initiative guarantees a steady market for smallholders and stimulates rural economies.

However, scaling up to full production requires overcoming significant logistical hurdles within the domestic agricultural supply chain. Local manufacturers routinely struggle with erratic electricity supply, high fuel costs, and poor transport infrastructure connecting farms to urban processing hubs. To protect raw inputs from spoilage, the programme includes parallel investments in cold-chain storage and rural aggregation centres. Regulators are also working to standardise the chemical testing of local crops to eliminate aflatoxin contamination, which frequently ruins groundnut harvests.

The financial sustainability of the project hinges on guaranteed procurement commitments from both federal and state governments. While the European Union provides initial capital to upgrade factories, Nigerian authorities must purchase the finished therapeutic foods for their public health clinics. De Luca emphasized that international donor funding cannot replace long-term domestic budgetary allocations for child nutrition. Moving forward, the state must treat malnutrition treatment as a core healthcare obligation rather than an emergency charitable campaign.

This intervention represents a broader shift in how international partners approach development assistance in Sub-Saharan Africa. Transitioning from importing finished relief goods to building local factories creates skilled jobs and preserves scarce foreign exchange reserves. Success will depend on whether local manufacturers can maintain competitive pricing once foreign subsidies eventually wind down. For now, the partnership establishes a blueprint for agricultural value addition that turns a public health crisis into an industrial opportunity.